Literature DB >> 16321841

Amylase: a disease activity index in multiple myeloma?

Massimiliano Pinelli1, Massimo Bindi, Javier Rosada, Paola Scatena, Maido Castiglioni.   

Abstract

This study reports a case of a patient with lambda-light chain multiple myeloma who developed a high hyperamylasaemia of the salivary type during the disease and soon afterwards died. Ectopic production of amylase by myeloma cells has been described in a few cases and demonstrated by tissue culture and immunohistochemical techniques. The common characteristics of these cases were: salivary amylase isoenzyme increase, high tumor mass, extensive extra-medullary spread, extensive bone destruction and poor prognosis. In patients with amylase-producing multiple myeloma, the onset of hyperamylasaemia heralds a rapid disease progression; therefore, in these patients, a simple test such as serum amylase may represent a reliable disease activity index and provide an additional prognostic information.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16321841     DOI: 10.1080/10428190500262144

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  A case of salivary-type amylase-producing multiple myeloma presenting as mediastinal plasmacytoma and myelomatous pleural effusion.

Authors:  Soon Jung Ok; In-Suk Kim; Eun Yup Lee; Jeong-Eun Kang; Sun-Min Lee; Moo-Kon Song
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

2.  Carcinoembryonic antigen-producing multiple myeloma detected by a transcription-reverse transcription concerted reaction system.

Authors:  Ken Kaito; Hiroko Otsubo; Shinobu Takahara; Miyuki Hyouki; Masaki Abe; Ikurou Abe; Noriko Usui
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.

Authors:  Shohei Mizuno; Ichiro Hanamura; Akinobu Ota; Sivasundaram Karnan; Tomoko Narita; Masaki Ri; Motonori Mizutani; Mineaki Goto; Mayuko Gotou; Norikazu Tsunekawa; Masato Shikami; Shinsuke Iida; Yoshitaka Hosokawa; Hiroshi Miwa; Ryuzo Ueda; Masakazu Nitta; Akiyoshi Takami
Journal:  Int J Hematol       Date:  2015-09-04       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.